Tadalafil topical - Callitas Therapeutics

Drug Profile

Tadalafil topical - Callitas Therapeutics

Alternative Names: Extrinsa

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Callitas Therapeutics
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Female sexual dysfunction

Most Recent Events

  • 01 Nov 2017 Callitas Therapeutics receive a successful response from the US Food and Drug Administration in its Pre-IND Meeting Request Written Response for Tadalafil topical for the treatment of Female sexual dysfunction
  • 11 Oct 2017 Callitas Therapeutics plans to initiate clinical trials for Female sexual dysfunction in the first quarter of 2018
  • 18 Jul 2017 Preclinical trials in Female sexual dysfunction in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top